|
Example
of Cellular Derived Gene
Clone 3B516: (5,820 nt). Codes for UL141, UL144,
truncated UL145, and 3 divergent copies of gene
matching to human
MGSA/Gro-alpha. This is a chemokine with
potential oncogenic activity (in melanomas and other
tumors). Two of the 3
copies of the gene lack a major intron
present in genomic DNA. This suggests recombination
with RNA rather than DNA.
Alignments of Predicted Amino
Acids of Stealth Virus Genes With MGSA/Gro-alpha
Stealth Gene A 4938 NPRFLGVTLLLMSLIAY----
CQSTTELRCQCTQTVQGIHPKNIQSVSIKDKGPNCPN
5099 NPR
L V LLL+
L+A TELRCQC QT+QGIHPKNIQSV++K GP+C
Human MGSA Gene 12 NPRLLRVALLLLLLVAAGRRAAGASVATELRC
QCLTLQGIHPKNIQSVNVKSPGPHCAQ71
Stealth Gene A 5100 QEVIATLKNGQKVCLNPTAPMVQKILKKTITDN 5198
EVIATLKNG+K CLNP +P+V+KI++K + +
Human
MGSA Gene 72 TEVIATLKNGRKACLNPASPIVKKIIEKMLNSD
104
Stealth
Gene B 5469 LLVATLLGTLLASTMVFADK----
EERCLCPKTIQGIHPKNIQSVELHEPRDMCPNVEVM 5636
L VA
LL L+A+ A E RC C +T+QGIHPKNIQSV + P C EV+
Human MGSA Gene 16
LRVALLLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPK
NIQSVNVKSPGPHCAQTEVI
75
Stealth Gene B 5637
*VCWYCVIIGKLAHEITYNSLYFSYLHSAKLKNGNEVCLNT
EGPMVKKIIEKM 5795 intron
A LKNG + CLN P+VKKIIEKM
Human
MGSA Gene 76 ---------------------------ATLKNGRKACLNPASPIVKKIIEKM
100
Stealth Gene C 4583 SPRFLAVALLIVSLIAYSESSQG------IRCECKKGTQKIPENKIV
VKKMKRPSGPNHP
4744 +PR L VALL++ L+A + G +RC+C + Q
I I +K
P GP+
Human
MGSA Gene 12
NPRLLRVALLLLLLVAAGRRAAGASVATELRCQCLQTLQGIHP
KNIQSVNVKSP-GPHCA
70
Stealth Gene C 4745 RTEVKDSTKQPGRDPMGRPVS
4807
+TEV
+T + GR P S
Human
MGSA Gene 71 QTEV-IATLKNGRKACLNPAS 90
Additional cellular genes have been identified in
several clones obtained from vira DNA isolated from
the stealth virus culture. Many of the genes have
highly reiterated/repeat sequences. Some of the
sequences match to endogenous reverse transcriptase,
suggesting a possible mechanism whereby
recombinations invoving cellular RNA can be back
translated into viral incorporated cellular DNA.
Conclusions
Atypically structured,
non-inflammation inducing cytopathic viruses
definetely exist.
Some of these viruses were derived from simian CMV
and have presumably entered
the human population from SCMV contaminated
batches of live polio vaccines.
Non-inflammatory
cytopathic viruses are grouped under the term
"stealth." They can
be regularly cultured from patients with
complex multi-system illnesses, including
various cancers. Positive stealth virus
cultures were found in approximately 10% of
University students donating blood for
transfusion. Community outbreaks do occur.
Stealth-adaptation is considered to be a generic
process that can involve many
types of cytopathic viruses. It presumably
occurs through the loss of genes
coding for major antigens normally targeted
by the cellular immune system.
Tissue culture
provides the best method to screen for
stealth-adapted viruses.
Viral cultures can also provide useful
insights into pathology, including formation
of lipids, and of protease-resistant protein
complexes.
The production
of lipids and pigmented materials is viewed as a
reparative
process helping to maintain cell viability. There is
a marked reduction in the
intensity of the CPE if the culture medium is
not frequently replaced.
Bacteria and
cell-derived genes are present in the SCMV-derived
stealth virus
culture. This important finding indicates the
potential intermixing of cellular, viral
and bacterial genes in the creation of new
highly pathogenic organisms. Viteria
is used to define viruses with bacterial
sequences.
Atypical bacteria can
commonly be cultured from stealth virus
infected patients.
Stealth viruses
are found in cancer patients, many of who have
symptoms of an
underlying neuropsychiatric illness. The
prospect of bacteria transmitting cancer
causing viruses is a very serious and urgent
public health concern.
Bacterial genes
can help explain partial and inconsistent
serological and/or PCR
diagnostic findings for mycoplasma, (in CFS,
Gulf War Syndrome): Borrelia (in
"chronic Lyme disease"), streptococcus (in
PANDAS), etc.
Apparent
expansion of chemokines and chemokines-receptor
genes provide an
adjunctive approach to anti-stealth virus
therapy. Many therapeutic agents are
available that can lead to cytokine/chemokine
suppression.
Ongoing Research Program
• Complete the sequencing of SCMV and SCMV-derived
stealth virus
• Test for passage of this virus through bacteria
using molecular methods
• Characterize lipids and proteins synthesized in
stealth virus cultures
• Survey patient populations for evidence of stealth
virus infections and for any
disease-related characteristics of their positive
cultures
• Determine if vaccines can activate a stealth virus
infection and/or pathology
• Sequence additional stealth virus isolates,
especially from cancer patients
• Conduct clinical trials on substances shown to
inhibit stealth virus CPE
• Educate clinicians on the multi-system nature of
stealth virus infections
Guiding
Quotes:
"One can only see what one
observes, one observes only the things that are
already in the mind."
Alphonse
Bertollin, 1853-1914.
"The
more I look, the more I see, and the more I see, the
more I look for."
Teihard
de Chardin, 1881-1914.
PUBLICATIONS
1. Martin WJ, Zeng LC, Ahmed K, Roy M.
Cytomegalovirus-related sequences in an atypical
cytopathic virus repeatedly isolated
from a patient with the chronic fatigue
syndrome. Am. J. Path. 145: 441-452, 1994.
2.
Martin WJ. Stealth virus isolated from an autistic
child. J. Aut. Dev. Dis. 25:223-224,1995
3. Martin WJ, Ahmed KN, Zeng LC, Olsen J-C, Seward
JG, Seehrai JS. African green monkey origin of the
atypical cytopathic
'stealth virus' isolated from a patient with
chronic fatigue syndrome. Clin. Diag. Virol. 4:
93-103, 1995.
4. Martin WJ, Glass RT. Acute encephalopathy induced
in cats with a stealth virus isolated from a patient
with chronic fatigue
syndrome. Pathobiology 63: 115-118, 1995.
5. Gollard RP, Mayr A, Rice DA, Martin WJ.
Herpesvirus-related sequences in salivary gland
tumors. J. Exp. Clin. Can. Res.
15: 1-4, 1996.
6.
Martin WJ. Genetic instability and fragmentation of
a stealth viral genome. Pathobiology 64:9-17, 1996.
7. Martin WJ. Severe stealth virus encephalopathy
following chronic fatigue syndrome-like illness:
Clinical and histopathological
features. Pathobiology 64:1-8, 1996.
8.
Martin WJ. Stealth viral encephalopathy: Report of a
fatal case complicated by cerebral vasculitis.
Pathobiology 64:59-63, 1996.
9. Martin WJ. Simian cytomegalovirus-related stealth
virus isolated from the cerebrospinal fluid of a
patient with bipolar
psychosis and acute encephalopathy.
Pathobiology 64:64-66, 1996.
10.
Martin WJ, Anderson D: Stealth virus epidemic in the
Mohave Valley. Initial report of viral isolation.
Pathobiology 65:51-56, 1997.
11.
Martin WJ. Cellular sequences in stealth viruses.
Patobiology 66:53-58, 1998.
12.
Martin WJ. Bacteria related sequences in a simian
cytomegalovirus-derived stealth virus culture. Exp
Mol Path. 66: 8-14, 1999.
13.
Martin WJ. Stealth adaptation of an African green
monkey simian cytomegalovirus. Exp Mol Path. 66:3-7,
1999.
14. Martin WJ. Melanoma Growth stimulatory activity
(MGSA/GRO-alpha) chemokine genes incorporated into
an African green
monkey simian cytomegalovirus (SCMV)-derived
stealth virus. Exp Mol Path. 66: 15-18,1999.
15. Martin WJ, Anderson D. Stealth Virus Epidemic in
the Mohave Valley: Severe vacuolating encephalopathy
in a child
presenting with a behavioral disorder. Exp Mol Path.
66:19-30 1999.
16. Martin WJ. Chemokine receptor-related sequences
in an African green monkey simian cytomegalovirus (SCMV)-derived
stealth virus. Exp Mol Path. 69: 10-16, 2000.
17.
Martin WJ. Stealth viruses. Explore 10: Number 4,
17-21, 2001.
18.
Martin WJ. Chronic fatigue syndrome among
clinicians: A potential role of
occupational exposure to stealth viruses.
Explore
10:
Number 5, 7-10, 2001
19.
Martin WJ. Chemokines and stealth viruses. A
blueprint for therapy in infected humans and
animals. Explore 11, Number 1, 7-11, 2002.
|
